Appian Selected by Accenture as a Core Partner in the INTIENT Network for Life Sciences

Rhea-AI Summary

Appian (NASDAQ: APPN) has joined Accenture's INTIENT partner ecosystem as a core partner aimed at enhancing integration between independent software vendors (ISVs) and life science companies. The partnership focuses on improving drug discovery and patient outcomes through the Accenture INTIENT Platform, which facilitates collaboration and efficiency in the life sciences sector. Appian's low-code development capabilities will allow organizations to build applications significantly faster, thereby supporting nine of the world's top ten drug and biotech firms.

Positive

• Partnership with Accenture enhances Appian's visibility in the life sciences sector.
• Integration with the INTIENT Platform allows for improved drug discovery efforts.
• Low-code capabilities can accelerate application development by up to 20x.

Negative

• None.

MCLEAN, Va., Jan. 8, 2021 /PRNewswire/ -- Appian (NASDAQ: APPN) today announced that it has joined Accenture's INTIENT partner ecosystem as a core partner. The ecosystem is designed to help independent software vendors (ISVs) and life science companies integrate more effectively to accelerate drug discovery efforts and improve patient outcomes.

The INTIENT Network is an integral part of Accenture's INTIENT Platform that enables insights and collaboration across the life sciences enterprise to improve productivity, efficiency, and innovation in drug discovery. Accenture has partnered with Appian to integrate low-code development into the INTIENT platform.

The Appian Low-Code Automation Platform allows enterprises to build applications up to 20x faster than traditional code. By providing a single interface that unifies data, process, people and the digital workforce, Appian helps organizations improve digital innovation and optimize business outcomes. Industry leaders trust Appian to improve customer experience, achieve operational excellence, and simplify global risk management and compliance.

"We are proud to work with Accenture to jointly support research, innovation, and better outcomes for the Life Sciences industry," said Marc Wilson, Founder and Senior Vice President of Global Partnerships and Industries at Appian. "Our ability to accelerate business processes, unify enterprise data, and simplify global compliance is why nine of the world's top 10 drug and biotech organizations use Appian."

As part of the INTIENT partner ecosystem, Appian's platform can be accessible across the INTIENT product suites.

"Our open partner network is one of the ways we're bringing innovation to our clients through the Accenture INTIENT Platform," said Jill Schulte, managing director in Accenture's Life Sciences practice. "Appian's integration into the INTIENT Platform enables low-code workflow creation and management to accelerate the building of applications for our clients and ultimately for the benefit of their customers and patients."

To learn more about Accenture's INTIENT Platform, go to https://www.accenture.com/us-en/services/life-sciences/intient

To request a free trial of the Appian Low-code Automation Platform, go to https://www.appian.com/platform/free-trial/.

About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications. Many of the world's largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance. For more information, visit www.appian.com.

View original content:http://www.prnewswire.com/news-releases/appian-selected-by-accenture-as-a-core-partner-in-the-intient-network-for-life-sciences-301203634.html

SOURCE Appian

FAQ

What is the significance of Appian joining Accenture's INTIENT partner ecosystem?

Appian's partnership with Accenture is intended to enhance integration between software vendors and life sciences companies, improving drug discovery and patient outcomes.

How does Appian's low-code platform benefit drug discovery?

The low-code platform allows for faster application development, which can enhance efficiency and productivity in drug discovery processes.

Which companies are involved in the INTIENT partner ecosystem?

Appian has become a core partner in the INTIENT ecosystem alongside Accenture, which connects various independent software vendors and life science companies.

What is the impact of this partnership on Appian's market position?

This partnership is expected to strengthen Appian's position in the life sciences market by enhancing its service offerings and visibility among top industry players.

When was the announcement made regarding Appian's partnership with Accenture?

The announcement was made on January 8, 2021.